Right Ventricular Function After Successful Reopening of Right Coronary Versus Left Circumflex Chronic Total Occlusions
Changes in Right Ventricular Function Following Successful Right Coronary Versus Left Circumflex Chronic Total Occlusion Revascularization
This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.
The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Design and setting:
Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.
Cohort formation:
Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.
Recruitment schedule:
Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.
Assessments:
Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.
Imaging:
Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.
Anatomical characterization:
Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.
Sample-size rationale:
The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.
Analysis:
The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.
Quality and ethics:
A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Amr A. A. Othman
- Número de telefone: +201004674109
- E-mail: amr.osman@med.aun.edu.eg
Locais de estudo
-
-
-
Asyut, Egito
- Assiut University Heart Hospital
-
Contato:
- Amr A. Othman
- Número de telefone: +201004674109
- E-mail: amr.osman@med.aun.edu.eg
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.
Descrição
Inclusion Criteria:
- Age 18 years or older.
- Clinically stable, with one native right coronary or left circumflex coronary artery chronic total occlusion, defined by TIMI 0 flow and documented or estimated duration of at least three months.
- Independently selected for clinically indicated elective PCI.
- Sinus rhythm and interpretable baseline RV-focused echocardiographic images.
- Written informed consent before research procedures.
- For inclusion in the main comparison: technically successful index CTO PCI, defined as residual stenosis less than 30% with final TIMI 3 flow.
Exclusion Criteria:
- Acute coronary syndrome or myocardial infarction within 30 days.
- Decompensated heart failure.
- A second untreated chronic total occlusion.
- Previous coronary artery bypass graft surgery.
- Significant congenital heart disease.
- Moderate or severe valvular heart disease.
- Severe nonischemic pulmonary disease or pulmonary hypertension dominating RV dysfunction.
- Persistent atrial fibrillation or paced rhythm preventing comparable analysis.
- Inadequate baseline RV tracking.
- Planned non-target revascularization during follow-up; clinically required other-vessel treatment should be completed before baseline when stable.
No arbitrary LVEF threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Successful RCA CTO PCI
Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol. |
Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure. Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required. |
|
Successful LCX CTO PCI
Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol. |
Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required. Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in right ventricular free-wall longitudinal strain magnitude
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in right ventricular four-chamber longitudinal strain magnitude
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in right ventricular fractional area change
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in tricuspid annular plane systolic excursion
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in tricuspid annular systolic tissue-Doppler velocity
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in right ventricular basal diameter
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in Canadian Cardiovascular Society angina class
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in New York Heart Association functional class
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in basal right ventricular free-wall segmental longitudinal strain magnitude
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in mid right ventricular free-wall segmental longitudinal strain magnitude
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
|
Change in apical right ventricular free-wall segmental longitudinal strain magnitude
Prazo: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients. |
Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Cadeira de estudo: Hatem A. Helmy, MD, Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University
Publicações e links úteis
Publicações Gerais
- Blessing R, Drosos I, Molitor M, Munzel T, Wenzel P, Gori T, Dimitriadis Z. Evaluation of right-ventricular function by two-dimensional echocardiography and two-dimensional speckle-tracking echocardiography in patients with successful RCA CTO recanalization. Clin Res Cardiol. 2023 Oct;112(10):1454-1462. doi: 10.1007/s00392-023-02259-4. Epub 2023 Aug 1.
- Galassi AR, Vadala G, Werner GS, Cosyns B, Sianos G, Hill J, Dudek D, Picano E, Novo G, Andreini D, Gerber BLM, Buechel R, Mashayekhi K, Thielmann M, McEntegart MB, Vaquerizo B, Di Mario C, Stojkovic S, Sandner S, Bonaros N, Luscher TF. Evaluation and management of patients with coronary chronic total occlusions considered for revascularisation. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, and the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2024 Feb 5;20(3):e174-e184. doi: 10.4244/EIJ-D-23-00749.
- Mukherjee M, Rudski LG, Addetia K, Afilalo J, D'Alto M, Freed BH, Friend LB, Gargani L, Grapsa J, Hassoun PM, Hua L, Kim J, Mercurio V, Saggar R, Vonk-Noordegraaf A. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025 Mar;38(3):141-186. doi: 10.1016/j.echo.2025.01.006.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- AssiutU-CARD-AAAO-0002
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The IPD might not be shared according to the local institutional policy.
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .